SW948 Xenograft Model Service for Colon Cancer

The SW948 xenograft model is a validated preclinical platform for evaluating therapeutic strategies in colon adenocarcinoma, offering robust tumor formation and clinically relevant molecular characteristics. Alfa Cytology provides a comprehensive SW948 Xenograft Model Service for Colon Cancer, delivering reproducible tumor models with integrated endpoint analysis to accelerate your preclinical drug development pipeline.

Overview of SW948 Xenograft Model for Colon Cancer

The SW948 cell line was established from a colorectal adenocarcinoma specimen obtained from an 81-year-old female patient diagnosed with Dukes' stage C disease. As an adherent epithelial cell line, SW948 exhibits robust tumorigenicity in immunodeficient mice, with tumors developing within 21 days at 100% frequency following subcutaneous inoculation. The cell line expresses multiple oncogenes including c-myc, K-ras, H-ras, N-ras, myb, and fos, and produces carcinoembryonic antigen (CEA) and colon-specific antigen (CSAp), making it a representative model for studying colorectal cancer biology and therapeutic intervention.

Genetically, SW948 is classified as microsatellite stable (MSS) with chromosomal instability (CIN-positive) and carries a KRAS Q61L activating mutation, a PIK3CA E542K mutation, and a TP53 G117fs frameshift mutation. The cell line has been extensively utilized in xenograft studies investigating combination therapies including TRA-8 anti-DR5 antibody with CPT-11, pertuzumab with irinotecan, and FOLFOX resistance mechanisms. SW948 xenografts demonstrate moderate sensitivity to TRA-8-mediated cytotoxicity in vitro and respond to CPT-11 monotherapy with significant tumor growth inhibition, while combination regimens have shown enhanced anti-tumor efficacy including complete regressions in preclinical settings.

Figure 1. The miR-335 affects the colon cancer cell growth. (Yang, Chuang, et al., 2020)

Cell Line Information: SW948

The following table summarizes the comprehensive characteristics of the SW948 cell line, derived from authenticated sources and peer-reviewed literature.

Our Services

Alfa Cytology offers a fully validated SW948 Xenograft Model Service for Colon Cancer, encompassing tumor establishment, treatment administration, longitudinal tumor monitoring, and comprehensive endpoint analysis including histopathology, biomarker profiling, and pharmacokinetic assessment. Our preclinical platform is designed to support your compound efficacy, toxicity, and mechanism-of-action studies with standardized protocols and rigorous quality control, ensuring reproducible data to advance your oncology drug development programs.

Workflow of SW948 Xenograft Model Construction

The construction of the SW948 xenograft model follows a standardized, multi-step workflow that ensures consistent tumor establishment and reliable therapeutic evaluation. Each phase is executed under controlled conditions with documented quality parameters to maintain reproducibility across studies.

1. Cell Line Authentication and Preparation: SW948 cells are authenticated via short tandem repeat (STR) profiling and verified for mycoplasma contamination prior to expansion. Cells are cultured under standard conditions and harvested at optimal confluence for maximal viability.
2. Cell Suspension and Matrigel Preparation: Harvested SW948 cells are resuspended at a concentration of 1 x 10^7 cells in 100-200 microL of serum-free medium mixed with Matrigel to enhance engraftment efficiency and tumor formation consistency.
3. Subcutaneous Injection into Immunodeficient Mice: The cell suspension is injected subcutaneously into the flank of female athymic nude mice (e.g., BALB/c nu/nu or NMRI nu/nu). Tumors typically become palpable within 14-21 days post-inoculation.
4. Tumor Monitoring and Randomization: Tumor growth is monitored twice weekly using digital calipers. Mice are randomized into treatment groups once tumors reach a target volume of approximately 75-150 mm^3, ensuring uniform baseline tumor burden across cohorts.
5. Therapeutic Intervention and Administration: Test compounds are administered according to predefined dosing schedules (e.g., intraperitoneal or intravenous routes). Concurrent vehicle control groups are included for comparative analysis. Body weight and general health status are recorded throughout the study.
6. Endpoint Assessment and Tissue Harvest: Upon reaching predetermined study endpoints (tumor volume limit or study duration), animals are humanely euthanized. Tumors are excised, weighed, photographed, and processed for downstream analyses including histopathology, immunohistochemistry, and molecular profiling.

Figure 2: Schematic workflow illustrating the derivation and construction of the SW948 Xenograft Model at Alfa Cytology.

Case Study-SW948 Xenograft Model Development

In a representative preclinical study, SW948 xenografts were established in immunodeficient mice to evaluate the efficacy of a novel therapeutic candidate. Tumors were successfully engrafted with 100% take rate and demonstrated consistent growth kinetics suitable for longitudinal pharmacological assessment. Treatment cohorts showed measurable differences in tumor volume progression compared to vehicle controls, with endpoint analyses revealing distinct histopathological and biomarker response patterns. Detailed quantitative data and statistical outcomes are available upon request and can be customized to align with specific client study objectives.

Why Choose Alfa Cytology?

Alfa Cytology is a specialized contract research organization dedicated to preclinical tumor model services. Our SW948 xenograft platform is built on validated methodologies, authenticated cell lines, and rigorous quality assurance to deliver dependable data for your drug development decisions.

• Validated SW948 xenograft model with documented 100% tumor take rate and reproducible growth kinetics in immunodeficient mice.
• Comprehensive molecular characterization support including KRAS, PIK3CA, and TP53 mutation status confirmation for mechanistic studies.
• Flexible study design accommodating single-agent, combination, and dose-escalation protocols with customized endpoint analyses.
• Integrated histopathology, immunohistochemistry, and biomarker profiling services to support mechanism-of-action and efficacy assessments.
• Standardized workflow with STR-authenticated cell lines, mycoplasma-free cultures, and documented quality control at every stage.
• Dedicated project management ensuring timely delivery of study reports with clear data presentation and statistical analysis.

Contact Us

Ready to advance your colon cancer preclinical research with a validated SW948 xenograft model? Contact us today to discuss your study requirements, receive a customized proposal, and learn how Alfa Cytology can accelerate your drug development timeline. Reach out to our team of scientific experts to explore how our SW948 Xenograft Model Service for Colon Cancer can be tailored to meet your specific research objectives.

For research use only. Not intended for any clinical use.